TriLink BioTechnologies® Signs Non-exclusive License and Supply Agreement with Elixirgen Scientific Japan for CleanCap® mRNA capping technology
TriLink CleanCap® mRNA capping technology now accessible to ESJ customers for non-commercial use
FUJISAWA (SEPTEMBER 26, 2023) – TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has entered into a non-exclusive License and Supply Agreement for TriLink’s CleanCap® mRNA capping technology with Elixirgen Scientific Japan, Inc (ESJ), a Japanese provider of synthetic mRNA contract development and manufacturing services.
Aligned to the terms of the agreement, TriLink® will supply its proprietary CleanCap® M6, CleanCap® AG 3’Ome, and CleanCap® AG cap analogs for use in ESJ’s mRNA development and manufacturing services, from pre-clinical through Phase III programs.
This agreement aligns with TriLink’s objective to enable greater access to CleanCap mRNA capping technologies. CleanCap technology produces an optimal Cap1 structure with over 95% efficiency, creating a one-pot solution that can help cut production processes by one week, and reduce overall manufacturing costs by 20-40% when compared to other capping methods.
“Our novel capping solutions improve mRNA function, help streamline manufacturing processes and maximize capped material yield, accelerating customer discoveries,” shared Drew Burch, EVP of TriLink’s Nucleic Acid Products division.
Since the launch of the first CleanCap analog in 2017, its technology continues to advance the mRNA capping industry and was used in one of the first commercially approved COVID-19 vaccines. Additionally, TriLink continues to evolve and expand its innovation with the launch of the CleanCap M6 analog, the most robust analog to date, with studies indicating increased mRNA expression by more than 30% versus enzymatic capping method.
“Having the opportunity to offer our customers TriLink’s industry-leading platforms and technology is pivotal,” shared Motoki Azuma, PhD, President of ESJ. “This access to premier reagents and other technology will fuel our customers’ R&D to support the growth of the industry at large.”
*Data and customer insights garnered from a market assessment conducted by a third-party consulting firm on behalf of TriLink in November 2022.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is helping to realize the power and potential of mRNA. As a global leader in nucleic acid and mRNA solutions for more than 25 years, TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its proprietary CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
For more information, visit trilinkbiotech.com
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit maravai.com
About Elixirgen Scientific Japan
Elixirgen Scientific Japan is a biotechnology company engaged in contract manufacturing of synthetic mRNA and stem cell-related products and services. Based on its technology for synthesizing mRNA in a cGMP-compliant environment, which is the standard for manufacturing and quality control of pharmaceutical products, and its technology for reproducibly inducing differentiation from iPS cells into various types of cells in about one week, the company aims to improve the quality of people's lives by supporting faster and lower-cost drug discovery.
For more information, contact [email protected]
